Literature DB >> 20378699

Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm.

Erik Kvam1, Michael R Sierks, Charles B Shoemaker, Anne Messer.   

Abstract

Soluble antibody fragments are desirable not only as potential therapeutic and diagnostic agents for extracellular targets but also as 'intrabodies' for functional genomics, proteomics and gene therapy inside cells. However, antibody fragments are notoriously aggregation-prone when expressed intracellularly, due in part to unfavorable redox potential and macromolecular crowding in cell cytoplasm. Only a small proportion of intrabodies are soluble in cytoplasm and little is known about the sequence determinants that confer such stability. By comparing the cytoplasmic expression of several related human single-chain variable fragments and camelid V(HH)s in mammalian cells, we report that intrabody solubility is highly influenced by CDR content and is improved by an overall negative charge at cytoplasmic pH and reduced hydrophilicity. We hypothesize that ionic repulsion and weak hydrophobic interactions compensate, to different extents, for impaired disulfide bond formation in cytoplasm, thereby decreasing the risk for intrabody aggregation. As proof of principle, we demonstrate that the soluble expression of an aggregation-prone positively charged intrabody is modestly enhanced via cis or trans acidification using highly charged peptide tags (3XFLAG tag, SV40 NLS). These findings suggest that simple sequence analysis and electrostatic manipulation may aid in predicting and engineering solubility-enhanced intrabodies from antibody libraries for intracellular use.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20378699      PMCID: PMC2865363          DOI: 10.1093/protein/gzq022

Source DB:  PubMed          Journal:  Protein Eng Des Sel        ISSN: 1741-0126            Impact factor:   1.650


  81 in total

1.  Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains.

Authors:  Pierre A Barthelemy; Helga Raab; Brent A Appleton; Christopher J Bond; Ping Wu; Christian Wiesmann; Sachdev S Sidhu
Journal:  J Biol Chem       Date:  2007-11-28       Impact factor: 5.157

2.  Analysis and improvements to Kabat and structurally correct numbering of antibody variable domains.

Authors:  K R Abhinandan; Andrew C R Martin
Journal:  Mol Immunol       Date:  2008-07-09       Impact factor: 4.407

3.  Sequence determinants of protein aggregation in human VH domains.

Authors:  Kip Dudgeon; Kristoffer Famm; Daniel Christ
Journal:  Protein Eng Des Sel       Date:  2008-10-28       Impact factor: 1.650

4.  Efficient isolation of soluble intracellular single-chain antibodies using the twin-arginine translocation machinery.

Authors:  Adam C Fisher; Matthew P DeLisa
Journal:  J Mol Biol       Date:  2008-11-01       Impact factor: 5.469

5.  Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity.

Authors:  Amber L Southwell; Ali Khoshnan; Denise E Dunn; Charles W Bugg; Donald C Lo; Paul H Patterson
Journal:  J Neurosci       Date:  2008-09-03       Impact factor: 6.167

6.  Characterizing antibody specificity to different protein morphologies by AFM.

Authors:  Min S Wang; Andleeb Zameer; Sharareh Emadi; Michael R Sierks
Journal:  Langmuir       Date:  2009-01-20       Impact factor: 3.882

7.  Anti-oligomeric single chain variable domain antibody differentially affects huntingtin and alpha-synuclein aggregates.

Authors:  Brent L Nannenga; Andleeb Zameer; Michael R Sierks
Journal:  FEBS Lett       Date:  2008-01-28       Impact factor: 4.124

8.  Hyper-acidic protein fusion partners improve solubility and assist correct folding of recombinant proteins expressed in Escherichia coli.

Authors:  Zhurong Zou; Lijuan Cao; Pei Zhou; Yu Su; Yonghong Sun; Wenjuan Li
Journal:  J Biotechnol       Date:  2008-05-27       Impact factor: 3.307

9.  A focused antibody library for selecting scFvs expressed at high levels in the cytoplasm.

Authors:  Pascal Philibert; Audrey Stoessel; Wei Wang; Annie-Paule Sibler; Nicole Bec; Christian Larroque; Jeffery G Saven; Jérôme Courtête; Etienne Weiss; Pierre Martineau
Journal:  BMC Biotechnol       Date:  2007-11-22       Impact factor: 2.563

10.  IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis.

Authors:  Xavier Brochet; Marie-Paule Lefranc; Véronique Giudicelli
Journal:  Nucleic Acids Res       Date:  2008-05-24       Impact factor: 16.971

View more
  24 in total

Review 1.  Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins.

Authors:  David C Butler; Julie A McLear; Anne Messer
Journal:  Prog Neurobiol       Date:  2011-11-18       Impact factor: 11.685

2.  Modifications of a signal sequence for antibody secretion from insect cells.

Authors:  Yuki Ohmuro-Matsuyama; Hideki Yamaji
Journal:  Cytotechnology       Date:  2017-06-05       Impact factor: 2.058

3.  A comprehensive in silico characterization of bacterial signal peptides for the excretory production of Anabaena variabilis phenylalanine ammonia lyase in Escherichia coli.

Authors:  Hajar Owji; Shiva Hemmati
Journal:  3 Biotech       Date:  2018-11-16       Impact factor: 2.406

4.  Exploiting Phage Display for Development of Novel Cellular Targeting Strategies.

Authors:  William Marsh; Amanda Witten; Sarah E Stabenfeldt
Journal:  Methods Mol Biol       Date:  2018

5.  Selection for intrabody solubility in mammalian cells using GFP fusions.

Authors:  Laurence Guglielmi; Vincent Denis; Nadia Vezzio-Vié; Nicole Bec; Piona Dariavach; Christian Larroque; Pierre Martineau
Journal:  Protein Eng Des Sel       Date:  2011-10-13       Impact factor: 1.650

6.  Rational engineering of antibody therapeutics targeting multiple oncogene pathways.

Authors:  Jonathan Fitzgerald; Alexey Lugovskoy
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

Review 7.  Engineered Autonomous Human Variable Domains.

Authors:  Johan Nilvebrant; Peter M Tessier; Sachdev S Sidhu
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

8.  Single chain variable fragment antibodies block aggregation and toxicity induced by familial ALS-linked mutant forms of SOD1.

Authors:  Ghanashyam D Ghadge; John D Pavlovic; Sujatha P Koduvayur; Brian K Kay; Raymond P Roos
Journal:  Neurobiol Dis       Date:  2013-04-20       Impact factor: 5.996

9.  Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies.

Authors:  Shubhada N Joshi; David C Butler; Anne Messer
Journal:  MAbs       Date:  2012-08-28       Impact factor: 5.857

Review 10.  Intrabodies as neuroprotective therapeutics.

Authors:  Anne Messer; Shubhada N Joshi
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.